Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Amazon Explores AI Content Marketplace With Media Publishers 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Heidelberg, Germany, March 15, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today the presentation of preclinical data for the Company's AFM24 program at the AACR Annual Meeting 2018 in Chicago, IL.
Poster Presentation
Abstract: Pharmacokinetics and in vitro/in vivo characterization of high-affinity bispecific EGFR/CD16A NK cell engagers for the treatment of EGFR-expressing tumors (#2786)
Session: PO.IM02.11 - Therapeutic Antibodies, Including Engineered Antibodies 2
Date and Time: Monday, April 16, 2018 1:00 PM - 5:00 PM (CT)
Location: McCormick Place South, Exhibit Hall A, Poster Section 34/Board 19, Chicago, IL
Full abstract of the presentation can be accessed on the AACR website at www.aacr.org
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected], [email protected]
